The injection of AxCA-IFN showed remarkable tumour suppressive effects in a dose-dependent manner, whereas recombinant IFN-α protein therapy failed to produce a significant therapeutic response (Figure 1), suggesting that an antitumour effect needs a sustained and efficient local expression of IFN-α. The gene discussed is IFNA2; the disease is neoplasm.